TW224053B - - Google Patents

Info

Publication number: TW224053B
Authority: TW; Taiwan
Prior art keywords: thymosin; immune system; potentiating; pref; fragment
Prior art date: 1991-09-13

Application number

TW081101971A

Other languages

English (en)

Original Assignee

Paul B Chretien

Milton G Mutchnick

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-13

Filing date

1992-03-16

Publication date

1994-05-21

1992-03-16 Application filed by Paul B Chretien, Milton G Mutchnick filed Critical Paul B Chretien

1994-05-21 Application granted granted Critical

1994-05-21 Publication of TW224053B publication Critical patent/TW224053B/zh

Links

LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 4
108010046075 Thymosin Proteins 0.000 abstract 3
102000007501 Thymosin Human genes 0.000 abstract 3
108010078233 Thymalfasin Proteins 0.000 abstract 1
102400000800 Thymosin alpha-1 Human genes 0.000 abstract 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
229960004231 thymalfasin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Virology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Beans For Foods Or Fodder (AREA)

TW081101971A 1991-09-13 1992-03-16 TW224053B (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US75954491A	1991-09-13	1991-09-13

Publications (1)

Publication Number	Publication Date
TW224053B true TW224053B (zh)	1994-05-21

Family

ID=25056052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW081101971A TW224053B (zh)	1991-09-13	1992-03-16

Country Status (23)

Country	Link
US (3)	US6001799A (zh)
EP (1)	EP0603305B1 (zh)
JP (1)	JP3228512B2 (zh)
KR (1)	KR100254082B1 (zh)
AT (1)	ATE152914T1 (zh)
AU (1)	AU667327B2 (zh)
CA (1)	CA2119006C (zh)
CZ (1)	CZ286827B6 (zh)
DE (1)	DE69219782T2 (zh)
DK (1)	DK0603305T3 (zh)
ES (1)	ES2103966T3 (zh)
FI (1)	FI107879B (zh)
GR (1)	GR3024025T3 (zh)
HK (1)	HK1021687A1 (zh)
HU (1)	HU221006B1 (zh)
MX (1)	MX9205240A (zh)
NO (1)	NO941310D0 (zh)
RO (1)	RO111991B1 (zh)
RU (1)	RU2104010C1 (zh)
SG (1)	SG64897A1 (zh)
TW (1)	TW224053B (zh)
WO (1)	WO1993005806A1 (zh)
ZA (1)	ZA926964B (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW224053B (zh) *	1991-09-13	1994-05-21	Paul B Chretien
SG64892A1 (en) *	1992-02-06	1999-05-25	Sciclone Pharmaceuticals	Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) *	1992-07-13	2002-08-08	Government Of The United States Of America As Represented By The Secretary Of The Army	Composition and method of treating hepatitis B
EP0627930A4 (en) *	1992-07-13	1997-08-20	Kenneth E Sherman	COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) *	1993-03-05	2001-10-17	施塞克龙药品公司	治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) *	1993-06-02	2001-03-13	Sciclone Pharmaceuticals, Inc.	Combination therapy method for treating chronic hepatitis B
US5468729A (en) *	1993-10-26	1995-11-21	Alpha 1 Biomedicals	Method for treatment of autoimmune hepatitis
DE69332982T2 (de) *	1993-11-05	2004-09-09	Alpha 1 Biomedicals, Inc.	Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung
JP3837769B2 (ja) *	1995-06-12	2006-10-25	大塚製薬株式会社	抗ウイルス剤
BR9707772A (pt) *	1996-02-28	2000-01-04	Ifi Istituto Farmacoterapico I	Composições farmacêuticas compreendendo alfa-interferon humano natural
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
MXPA02011691A (es)	2000-05-26	2004-05-17	Idenix Cayman Ltd	Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
WO2002011749A1 (en) *	2000-08-07	2002-02-14	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) *	2000-08-07	2007-04-24	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002044717A1 (en) *	2000-12-01	2002-06-06	Cornell Research Foundation	Animal model for flaviviridae infection
RU2211703C2 (ru) *	2001-06-08	2003-09-10	ООО НТЦ "Юпитер-2"	Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
JP2005504087A (ja) *	2001-09-28	2005-02-10	イデニクス（ケイマン）リミテツド	４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
CA2460341A1 (en) *	2001-10-05	2003-04-17	Intermune, Inc.	Methods of treating liver fibrosis and hepatitis c virus infection
DE60224435T2 (de)	2001-10-26	2009-01-02	Rhode Island Hospital	Thymosin-augmentation bei genetischer immunisierung
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) *	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
MY140819A (en)	2002-06-28	2010-01-29	Idenix Caymans Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
JP2005533824A (ja)	2002-06-28	2005-11-10	イデニクス（ケイマン）リミテツド	フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh)	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
PL377342A1 (pl)	2002-11-15	2006-01-23	Idenix (Cayman) Limited	Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2003300901A1 (en)	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
GB0301879D0 (en) *	2003-01-27	2003-02-26	Regent Res Llp	HCV combination therapy
JP4149296B2 (ja) *	2003-03-26	2008-09-10	株式会社ルネサステクノロジ	半導体記憶装置
ATE467422T1 (de) *	2003-03-28	2010-05-15	Sciclone Pharmaceuticals Inc	Behandlung von aspergillus-infektionen mit thymosin alpha 1
CN100342907C (zh) *	2003-03-28	2007-10-17	希克龙制药公司	胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用
US20100311656A1 (en) *	2003-04-23	2010-12-09	Sciclone Pharmaceuticals, Inc.	Treatment or prevention of respiratory viral infections with alpha thymosin peptides
PL2604620T5 (pl)	2003-05-30	2024-10-14	Gilead Pharmasset Llc	Zmodyfikowane fluorowane analogi nukleozydu
US20050075309A1 (en)	2003-07-25	2005-04-07	Richard Storer	Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005021007A1 (fr) *	2003-08-28	2005-03-10	Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir'	Prevention et traitement de l'hepatite virale b
KR20070011451A (ko)	2004-05-05	2007-01-24	예일 유니버시티	신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
NZ554442A (en)	2004-09-14	2011-05-27	Pharmasset Inc	Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
EP1976382B1 (en)	2005-12-23	2013-04-24	IDENIX Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) *	2006-03-10	2007-09-12	Tecnogen S.P.A.	Use of PTX3 for the treatment of viral diseases
CA2649063C (en) *	2006-05-02	2014-11-25	Luigina Romani	Use of thymosin .alpha.1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) *	2006-05-10	2008-11-01	Bcn Peptides, S.A.	Procedimiento para sintetizar timosinas.
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
TW200946541A (en) *	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
EP2349315A4 (en) *	2008-10-08	2012-07-04	Univ Miami	LYMPHOCYTE REGULATION AND APPLICATION
US8716263B2 (en)	2008-12-23	2014-05-06	Gilead Pharmasset Llc	Synthesis of purine nucleosides
EA019341B1 (ru)	2008-12-23	2014-02-28	Джилид Фармассет, Ллс.	Фосфорамидаты нуклеозидов
EA201100851A1 (ru)	2008-12-23	2012-04-30	Фармассет, Инк.	Аналоги нуклеозидов
US8716012B2 (en)	2009-05-08	2014-05-06	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
MX2012011171A (es)	2010-03-31	2013-02-01	Gilead Pharmasset Llc	Fosforamidatos de nucleosido.
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
JP6069215B2 (ja)	2010-11-30	2017-02-01	ギリアドファーマセットエルエルシー	化合物
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US8809354B2 (en)	2011-12-31	2014-08-19	Sheikh Riazuddin	3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) *	2012-11-09	2015-10-21	长春海悦药业有限公司	一种含有胸腺法新的药物组合物及其制剂
EP3038601B1 (en)	2013-08-27	2020-04-08	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1216056B (it) *	1988-03-11	1990-02-22	Sclavo Spa	Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) *	1991-03-29	1993-12-28	The George Washington University	Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (zh) *	1991-09-13	1994-05-21	Paul B Chretien

1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en not_active Ceased
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-08 HK HK98105712A patent/HK1021687A1/zh not_active IP Right Cessation
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310D0/no unknown
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0603305A1 (en)	1994-06-29
JP3228512B2 (ja)	2001-11-12
RO111991B1 (ro)	1997-04-30
US20070218033A1 (en)	2007-09-20
RU2104010C1 (ru)	1998-02-10
DK0603305T3 (da)	1997-09-01
NO941310L (no)	1994-04-12
EP0603305B1 (en)	1997-05-14
ES2103966T3 (es)	1997-10-01
JPH06510998A (ja)	1994-12-08
AU2644792A (en)	1993-04-27
US6001799A (en)	1999-12-14
US5849696A (en)	1998-12-15
CA2119006C (en)	2005-08-23
CZ55194A3 (en)	1994-10-19
ZA926964B (en)	1993-04-26
AU667327B2 (en)	1996-03-21
GR3024025T3 (en)	1997-10-31
DE69219782D1 (de)	1997-06-19
HUT75166A (en)	1997-04-28
WO1993005806A1 (en)	1993-04-01
MX9205240A (es)	1993-07-01
FI941133A0 (fi)	1994-03-10
FI941133L (fi)	1994-03-10
NO941310D0 (no)	1994-04-12
CZ286827B6 (cs)	2000-07-12
FI107879B (fi)	2001-10-31
HK1021687A1 (zh)	2000-06-23
DE69219782T2 (de)	1997-10-09
HU9400758D0 (en)	1994-06-28
KR100254082B1 (ko)	2000-09-01
SG64897A1 (en)	1999-05-25
HU221006B1 (hu)	2002-07-29
RU94022480A (ru)	1996-07-20
CA2119006A1 (en)	1993-04-01
ATE152914T1 (de)	1997-05-15

Publication	Publication Date	Title
TW224053B (zh)	1994-05-21
EP0635969A3 (en)	1995-05-24	Source verification procedures.
FI932254A7 (fi)	1993-07-02	Menetelmä dipalmitoyylifosfaridyylikoliinidispersioiden antamiseksi
EP0599209A3 (en)	1995-03-15	Process for the fractionation of a polyhydrogensilsesquioxane according to its molecular weight.
AU3022692A (en)	1993-06-24	Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
IT1267448B1 (it)	1997-02-05	Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina.
EP0528869A4 (en)	1994-03-24	PROCESS FOR TREATING A LESIONED ARTERIAL WALL DURING ANGIOPLASTY.
EP0618803A4 (en)	1995-03-22	POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
EP0717592A4 (en)	1997-12-29	METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
AU1668792A (en)	1992-12-21	Improved apparatus and method for aliquotting blood serum or blood plasma
GR3006630T3 (zh)	1993-06-30
ZA936799B (en)	1994-04-14	Method for treating symptoms associated with premenstrual syndrome by administering vitamin D or A combination of calcium and vitamin D
EP0467356A3 (en)	1992-05-20	Treatment system having gate device for decompression chamber
ZA921107B (en)	1993-08-16	Method of treating Type I diabetes.
SG46620A1 (en)	1998-02-20	Method and composition foor the treatment of autoimmune hepatitis
GB2271509B (en)	1995-03-08	Antivenom immunesera
NO894008D0 (no)	1989-10-06	Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
EP0649308A4 (en)	1994-06-22	PREVENTION OF HEMOLYSIS.
EP0648124A4 (en)	1996-05-08	METHOD FOR STIMULATING THE IMMUNE SYSTEM.
HU9402578D0 (en)	1994-11-28	Medicament for treating or preventing cerebrovascular diseases
EP0609358A4 (en)	1994-10-12	Methods for treatment of hyperlipidemia using azaspiranes.
ZA929418B (en)	1993-06-07	Recombinant vaccines and method of producing same.
EP0235904A3 (en)	1989-10-11	Treatment of allergy with thymopentin
EG19446A (en)	1995-03-30	Improved frog and method for the manufacture thereof.
EP0609335A4 (en)	1994-10-12	Methods for the treatment of hyperlipidemia using azaspiranes.